PhoenixBio Co Graham Number
The Graham Number of PhoenixBio Co (6190.T) as of Oct 13, 2026 is 513.26 JPY. In the previous year, Graham Number was 251.31 JPY — a change of 104.24% (higher).
Get this data via API
Financial Data API
Graham Number
513.26JPY
YoY
104.24%
Last updated:
Graham Number of PhoenixBio Co is 2026 513.26 JPY. Graham Number of PhoenixBio Co was 2025 251.31 JPY. It decreases by 104.24% higher compared to the previous year.
The PhoenixBio Co Graham Number history
3 Years
10 Years
25 Years
Max
Graham Number
Date
Graham Number
Jan 1, 2014
395.90 JPY
Jan 1, 2015
283.18 JPY
Jan 1, 2016
578.41 JPY
Jan 1, 2017
696.01 JPY
Jan 1, 2023
1,045.94 JPY
Jan 1, 2024
251.31 JPY
Jan 1, 2026
513.26 JPY
| YEAR | Graham Number | YoY |
|---|---|---|
| 513.26JPY | +104.24% | |
| 251.31JPY | -75.97% | |
| 1,045.94JPY | +50.28% | |
| 696.01JPY | +20.33% | |
| 578.41JPY | +104.26% | |
| 283.18JPY | -28.47% | |
| 395.90JPY | — |
Access this data via the Eulerpool API
PhoenixBio Co Stock analysis
What does PhoenixBio Co do? PhoenixBio Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about PhoenixBio Co stock
Graham Number of PhoenixBio Co is 513.26 JPY in 2026.
On Eulerpool you can find the complete historical development of Graham Number PhoenixBio Co since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
Quality — PhoenixBio Co
All Key Metrics — PhoenixBio Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth